-Business Standard/ NIPFP In the wake of the growing military tension on the India-China border, there have been calls for boycott of Chinese products. These have little impact on strategic reality. Equally, the plea that India cannot afford to do without Chinese imports is not a truism.   If bilateral tensions escalate, then there may be a scenario in which India and China cease to trade. How would the Indian economy be hit...

-The Telegraph A low tax regime is not enough; investors need to see demonstrable action to ease the pangs of doing business in India A wave of euphoria has swept through industry and stock markets since the finance minister, Nirmala Sitharaman, announced a sharp cut in corporate tax to an effective rate of 25.17 per cent. The effective tax rate will now go down sharply from a high of 34.94 per cent,...

-The Times of India NEW DELHI: Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering prices of drugs. While innovative and newer drugs for cancer, hepatitis C and rare diseases are out of reach of many due to their unaffordable prices,...

-Newsclick.in In an interview, the ‘father’ of India’s Green Revolution, says while technology is necessary, policies on procurement and public distribution are far more important in making agriculture economically viable and sustainable in the country. No one has played a more instrumental role in India’s self-sufficiency in food production than Dr MS Swaminathan — world-renowned agricultural scientist, known as the ‘Father of Green Revolution in India’. After getting a PhD from Cambridge...

-The Times of India NEW DELHI: In what is being seen as an attempt to delay launch of low priced generic medicines, multinational drug makers have asked the government to create a registry providing information about all drug applications pending manufacturing and marketing approval. The proposal, if accepted by the government, will help ‘Big Pharma’ pre-emptively challenge generic drug makers in court for allegedly infringing upon their patents and in turn blocking...